News Summary

Indian online pharmacy startup PharmEasy has experienced a significant drop in its valuation, now estimated at approximately $456 million. This marks a drastic decline from its peak valuation of $5.6 billion in 2021. The markdown comes after investor Janus Henderson reduced the value of its stake, which consisted of 12.9 million shares, to $766,043 from an initial purchase price of $9.4 million. Despite raising over $200 million earlier this year and preparing for an IPO next year, the startup faces substantial financial challenges, including debt obligations and a previous dependence on debt financing. PharmEasy, backed by investors such as Prosus, Temasek, TPG, and B Capital, had raised $417 million through a rights issue in 2023. However, the company has struggled to repay loans, including a $300 million loan from Goldman Sachs, further complicating its financial situation.